

Amgen completed its acquisition of Immunex Corporation on July 15, 2002. This archived Immunex press releases is provided for reference only.

FOR IMMEDIATE RELEASE, January 2, 2002

Immunex Announces Release Date of Fourth Quarter Earnings And Investor Conferences for January

SEATTLE - Immunex Corporation (Nasdaq: IMNX) will release fourth quarter and full-year 2001 financial results on Wednesday, January 23, 2002, after the close of U.S. financial markets. This announcement will be made available on the Immunex website at <http://www.immunex.com>, and on PRNewswire's website at <http://www.prnewswire.com>.

Additionally, Immunex executives will host a conference call and live audio webcast at 2:00 p.m. PST (5:00 p.m. EST) on January 23rd to discuss the company's financial results. The dial-in number for the earnings call is 719.457.2693 (ask for the Immunex call). The live webcast and replay can be accessed on the Immunex website at http://www.immunex.com/investor_fs3.html. Replay of the webcast will be available through January 30th, 2002.

Immunex has also scheduled a presentation at an investor conference in January 2002. For information about available webcasts and replays, visit the "Investor" page, "Events" section on the Immunex Corporation website at www.immunex.com/investor_fs3.html.

The summary of investor events for Immunex in January is as follows:

JP Morgan H&Q 20th Annual Healthcare Conference
January 8, 2002
San Francisco, CA

Immunex 4th Quarter/Full-Year 2001 Earnings
January 23, 2002
Seattle, WA (719.457.2693 - ask for the Immunex call)

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovations.

NOTE: Except for the historical information contained herein, this news release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, our supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation and other risk factors listed from time to time in reports filed by Immunex with the SEC, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operations and Our Stock Price" within our most recently filed Form 10-Q. The forward-looking statements contained in this news release represent our judgment as of the date of this release. Immunex undertakes no obligation to publicly update any forward-looking statements. An electronic version of this news release -- as well as additional information about Immunex of interest to investors, customers, future employees and patients -- is available on the Immunex home page at www.immunex.com.